Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
University of California, Irvine, Irvine, California University of California, San Diego, La Jolla, California University of California, Los Angeles Neuro-Oncology Program, Los Angeles, California Stanford, Stanford, California Miami Cancer Institute, Miami, Florida Massachusetts General Hospital, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts The Valley Hospital - Neurosurgeons of New Jersey, Ridgewood, New Jersey The Neurological Institute of New York Columbia University Medical Center, New York, New York Vanderbilt University Medical Center, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas Providence - Swedish Medical Center, Seattle, Washington